BR0212295A - Ensaio - Google Patents

Ensaio

Info

Publication number
BR0212295A
BR0212295A BR0212295-2A BR0212295A BR0212295A BR 0212295 A BR0212295 A BR 0212295A BR 0212295 A BR0212295 A BR 0212295A BR 0212295 A BR0212295 A BR 0212295A
Authority
BR
Brazil
Prior art keywords
potassium channel
assay
test
eag
compounds
Prior art date
Application number
BR0212295-2A
Other languages
English (en)
Inventor
Pamela May Greengrass
Michael Stewart
Claire Margaret Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0121440.2A external-priority patent/GB0121440D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0212295A publication Critical patent/BR0212295A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"ENSAIO". A invenção refere-se a um ensaio para estabelecer a afinidade de compostos no canal (K+) de potássio "ether-a-go-go" (EAG), em particular o canal de potássio EAG humano (hERG),utilizando um bloqueador de canal de potássio de retificação para o interior rotulado (IKR). Esse ensaio é útil para identificar compostos com efeitos indesejáveis em repolarização cardíaca no homem, em particular a propensão de prolongar o intervalo QT no eletrocardiograma.
BR0212295-2A 2001-09-04 2002-09-04 Ensaio BR0212295A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0121440.2A GB0121440D0 (en) 2001-09-04 2001-09-04 Assay
US32397301P 2001-09-20 2001-09-20
PCT/IB2002/003618 WO2003021271A2 (en) 2001-09-04 2002-09-04 Affinity-assay for the human erg potassium channel

Publications (1)

Publication Number Publication Date
BR0212295A true BR0212295A (pt) 2004-10-13

Family

ID=26246508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212295-2A BR0212295A (pt) 2001-09-04 2002-09-04 Ensaio

Country Status (8)

Country Link
EP (1) EP1423700A2 (pt)
JP (1) JP2005510691A (pt)
BR (1) BR0212295A (pt)
CA (1) CA2459265A1 (pt)
IL (1) IL160674A0 (pt)
MX (1) MXPA04002058A (pt)
PL (1) PL370539A1 (pt)
WO (1) WO2003021271A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701144D0 (sv) † 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
SE0302775D0 (sv) * 2003-10-20 2003-10-20 Astrazeneca Ab Chemical compound and assay
US7927820B2 (en) * 2004-07-20 2011-04-19 Janssen Pharmaceutica Nv Assay systems and methods for detecting molecules that interact with membrane channels
US7326772B2 (en) * 2005-05-12 2008-02-05 Penta Biotech, Inc. Peptide for assaying hERG channel binding
ATE462780T1 (de) 2005-12-21 2010-04-15 Hoffmann La Roche Stabile, herg darstellende zellkulturen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133010T2 (de) * 2000-07-14 2009-03-19 Merck & Co., Inc. Radioliganden- und bindungs-assay

Also Published As

Publication number Publication date
WO2003021271A3 (en) 2003-12-18
JP2005510691A (ja) 2005-04-21
MXPA04002058A (es) 2004-06-07
WO2003021271A2 (en) 2003-03-13
PL370539A1 (en) 2005-05-30
IL160674A0 (en) 2004-08-31
CA2459265A1 (en) 2003-03-13
EP1423700A2 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
DE60218721D1 (en) Pyrimidinone als melanin concentrating hormone receptor 1
UY27079A1 (es) Procedimiento para la preparación de un anticolinérgico
MA28172A1 (fr) 5,7-diaminopyrazolo [4,3-D] pyrimidines à activité inhibitrice de PDE-5
TWI319011B (en) Diagnosis and treatment of cancers and other conditions
TR200100410T2 (tr) 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
BR0210253A (pt) Processo para telomerização de olefinas não-cìclicas
BR9805706A (pt) Conjunto de assento para veículo que possui um banco amovível montado sobre corrediças.
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
GB0127903D0 (en) Improvements relating to organic compounds
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
NO992667L (no) Ny human <beta>2-integrin-<alfa>-subenhet
UY24561A1 (es) Analogos de la vitamina d3
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
BR0212295A (pt) Ensaio
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
SE9802574D0 (sv) Novel compounds
PT1121375E (pt) Composto de elevada pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ona
YU24000A (sh) Polimorfi dofetilida
DE69805002D1 (de) Kv2.1 antagonisten
BR0214244A (pt) Uso de uma ascomicina
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.